Specific nicotinic receptor subtypes (alpha3beta4 and alpha6beta4) modulated THC withdrawal in mice, and genetic variations in these same receptor genes were associated with cannabis disorder in humans.
Addiction pharmacologists, geneticists, researchers developing cannabis cessation medications
Mouse pharmacology, knockout genetics, and human genomics converged on the same nicotinic receptor subtypes
What the researchers found
Alpha3beta4 nAChR antagonist/partial agonist reduced THC withdrawal signs. Alpha5 and alpha6 nAChR knockout mice had decreased withdrawal. Beta2 and alpha7 knockouts showed no change. Human genetic association studies confirmed that variations in genes coding for alpha5, alpha3, beta4, and alpha6 nAChRs were associated with cannabis disorder phenotypes.
Why it matters
This identifies specific nicotinic receptor subtypes as potential medication targets for cannabis dependence, supported by converging evidence from animal pharmacology, knockout genetics, and human genomics.
The numbers in context
AuIB (alpha3beta4 antagonist) and AT-1001 (alpha3beta4 partial agonist) dose-dependently attenuated THC withdrawal. Alpha5 and alpha6 KO mice: decreased withdrawal. Beta2, alpha7 KO: no change. Human genes: CHRNA5, CHRNA3, CHRNB4, CHRNA6 associated with cannabis disorder.
How the study worked
Multi-approach study: pharmacological challenges in THC-dependent mice, knockout mouse models (alpha5, alpha6, beta2, alpha7 nAChRs), and human genetic association studies for cannabis disorder phenotypes.
What this study cannot tell us
Animal withdrawal model uses rimonabant-precipitated withdrawal which may not fully match human spontaneous withdrawal; human genetic associations are correlational; specific mechanism of nicotinic-cannabinoid interaction not fully elucidated.
How to read the evidence
Strong converging evidence from three complementary approaches (pharmacology, knockout mice, human genetics).
When this study was published
Published in 2020.
The bigger picture
The nicotinic-cannabinoid system interaction provides a novel therapeutic target class for cannabis dependence, leveraging existing knowledge from nicotine addiction pharmacology.
Questions still open
- Could existing nicotinic receptor drugs (like varenicline) help with cannabis cessation? Would alpha3beta4 partial agonists be effective and tolerable in human cannabis dependence?
Common questions
What do nicotine receptors have to do with cannabis addiction?
Could this lead to new treatments?
Read the original research
Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC dependence: Mouse and human studies.
Addiction biology, 25(1), e12691
Citation
Donvito, Giulia; Muldoon, Pretal P; Jackson, Kia J; Ahmad, Urslan; Zaveri, Nur T; McIntosh, J Michael; Chen, Xiangning; Lichtman, Aron H; Damaj, M Imad. (2020). Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC dependence: Mouse and human studies.. Addiction biology, 25(1), e12691. https://doi.org/10.1111/adb.12691
Explore the wider topic
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Is Rehab Necessary for Weed? An Honest Assessment
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit